Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Cipla gets EIR from USFDA for Invagen manufacturing facility

Jan 28, 2020, 10:29 IST

PTI

New Delhi, Jan 28 () Homegrown pharma major Cipla on Tuesday said it has received a report from the US health regulator indicating closure of the inspection at its US Invagen manufacturing facility.

"Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.

The shares of Cipla were trading at Rs 463.20 a piece on BSE in morning trade, down 0.31 per cent from the previous close. SID SID ANS ANS

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)